BIO KEY INTERNATIONAL INC — Form 8-K
Filed July 7, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
BIO-key International (Nasdaq: BKYI, market cap ~$4.9M) announced on July 7, 2026 that Nasdaq approved reinstatement of its common stock trading effective July 8, 2026, following a June 16 hearing panel determination that the company regained compliance with continued listing standards including minimum bid price and SEC filing requirements. The company remains subject to a Discretionary Panel Monitor for one year (until July 6, 2027). No financial metrics, share count changes, or specific remediation actions are detailed in the filing.
Why this rating
Trading halt reversal is material for a $4.9M public company—it preserves market access and liquidity. However, no new revenue, financing, or operational details provided; compliance restoration is necessary but not transformational.
See more from July 7, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.